Skip to main content
OpenTrials
Completed

NCT Number: NCT03961217

Return to Work Among Cancer Survivors With Treatment-induced Survivorship Syndromes

The investigators plan to investigate the consequences of late effects (radiation-induced survivorship syndromes) after radiotherapy in Gynecological and Prostate cancer survivors on return to work (Yes/No) and if RTW happened then time to RTW.

In addition, whether general health, type of work (occupation), work environment factors, individual factors (lifestyle, socioeconomic status etc.), contribute to the adverse late effects of radiotherapy and these Gynecological cancer survivors have a higher risk for disability pension/long term sickness absence (NOT Return to work).

Completed

Looking for future studies?

Notify Me

Key information

About this study

Occurrence of cancer diagnoses are rising, and both disease and treatments are aggressive. Due to advancement in medical technology, improved therapy and/or early detection the overall survival rates are also improving.

Some of the most common cancer types, such as breast cancer, prostate cancer, cervical cancer, and colorectal cancer have high cure rates when detected early and treated according to best practices. Many of these cancer survivors are of working age and are likely to return to work. Women who survive cervical cancer and men who survive testicular cancer typically have three to four decades left in working life.

However, return to work (RTW) among cancer survivors may not be similar to RTW among long-term sickness absentees due to other diagnoses. Cancer is a life threatening disease and cancer diagnose is a life changing event. The emotional shock after the cancer diagnosis may be associated with low psychological well-being even two years after prostate cancer surgery.

The successful cancer treatment concludes with the lifelong consequences of surgery, irradiation, cytotoxic chemotherapy, biological anticancer substances or other drugs in the treatment. The ionizing radiation that eliminates malignant cells may trigger long-lasting pathophysiological processes in the normal tissue and affect the health of the survivors with lifelong treatment-induced survivorship diseases. In a recent study, Steineck et al, identified five radiation-induced survivorship syndromes affecting bowel health in a cohort of gynecological cancer; urgency syndrome (30%), leakage syndrome (26%), excessive gas discharge(15%), excessive mucus discharge (16%) and blood discharge (10%).

There is a lack of knowledge about how these side effects of cancer treatment affect the degree of work ability and return to work. Clinical experience suggests that many cancer survivors have reduced work ability. There is a need for scientific studies that shed light on the side effects of cancer treatment and their relation to work ability.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 25 to 60 years (working age)
  • Employed at time of diagnosis
  • Treated for cancer
  • Suffering from at least one of Radiation-induced survivorship syndromes
  • First cancer & first time treatment for cancer,

Exclusion criteria

  • No other chronic disease
  • Chronic intestinal illness/surgery
  • Stage IV cancer
  • Recurrent cancer/Relapse

Treatment and study plan

Radiotherapy

Radiation

Radiotherapy as part of cancer treatment

Primary outcomes

  1. Return to work (RTW)

    Time frame: Five - Ten years after mapping Radiation-induced survivorship syndromes

    Information on Sickness absence for more than 14 days was obtained from the official registries in Sweden.

Secondary outcomes

  1. Time to Return to work

    Time frame: Five - Ten years after mapping Radiation-induced survivorship syndromes

    Sickness absence (more than 14 days) until the survivor returned to work. Also obtained from the official registries in Sweden.

Sponsors and collaborators

Lead sponsor

Sahlgrenska University Hospital

Other

Collaborators

  • Vastra Gotaland Region

Registry information

Important dates

Study start
1991
Primary completion
2006
Study completion
2016
First posted
May 23, 2019
Registry last updated
May 28, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.